Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 5 of 5

Publication Record

Connections

Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.
Mousa JJ, Sauer MF, Sevy AM, Finn JA, Bates JT, Alvarado G, King HG, Loerinc LB, Fong RH, Doranz BJ, Correia BE, Kalyuzhniy O, Wen X, Jardetzky TS, Schief WR, Ohi MD, Meiler J, Crowe JE
(2016) Proc Natl Acad Sci U S A 113: E6849-E6858
MeSH Terms: Animals, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibodies, Neutralizing, Antibodies, Viral, Antiviral Agents, Cell Line, Crystallography, X-Ray, Epitope Mapping, Epitopes, Humans, Mice, Mutagenesis, Palivizumab, Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus, Human, Viral Fusion Proteins
Added April 8, 2017
1 Communities
3 Members
0 Resources
17 MeSH Terms
Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma.
Feldman AS, He Y, Moore ML, Hershenson MB, Hartert TV
(2015) Am J Respir Crit Care Med 191: 34-44
MeSH Terms: Antibodies, Monoclonal, Humanized, Antiviral Agents, Asthma, Child, Preschool, Diet, Environmental Exposure, Epigenesis, Genetic, Genetic Predisposition to Disease, Humans, Infant, Microbiota, Palivizumab, Primary Prevention, Respiratory Syncytial Virus Infections, Respiratory Syncytial Viruses, Respiratory Tract Infections, Rhinovirus, Risk Factors, Severity of Illness Index, Tobacco Smoke Pollution
Added January 20, 2015
0 Communities
1 Members
0 Resources
20 MeSH Terms
Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein.
Bates JT, Keefer CJ, Slaughter JC, Kulp DW, Schief WR, Crowe JE
(2014) Virology 454-455: 139-44
MeSH Terms: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibodies, Neutralizing, Drug Resistance, Viral, Humans, Kinetics, Mutation, Palivizumab, Protein Binding, Respiratory Syncytial Viruses, Viral Fusion Proteins
Added February 2, 2015
0 Communities
1 Members
0 Resources
11 MeSH Terms
Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model.
Zeitlin L, Bohorov O, Bohorova N, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley KJ, Barnard DL, Bates JT, Crowe JE, Piedra PA, Gilbert BE
(2013) MAbs 5: 263-9
MeSH Terms: Animals, Antibodies, Monoclonal, Humanized, Antibodies, Neutralizing, Disease Models, Animal, Humans, Palivizumab, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus, Human, Sigmodontinae, Tobacco, Treatment Outcome
Added January 26, 2016
0 Communities
1 Members
0 Resources
11 MeSH Terms
Adherence to guidelines for respiratory syncytial virus immunoprophylaxis among infants with prematurity or chronic lung disease in three United States counties.
Carroll KN, Griffin MR, Edwards KM, Ali A, Zhu Y, Iwane MK, Szilagyi PG, Staat MA, Stevens TP, Hall CB, Williams JV, Hartert TV
(2012) Pediatr Infect Dis J 31: e229-31
MeSH Terms: Antibodies, Monoclonal, Humanized, Antiviral Agents, Chronic Disease, Humans, Infant, Infant, Newborn, Infant, Premature, Palivizumab, Practice Guidelines as Topic, Respiratory Syncytial Virus Infections, Time Factors, United States
Added December 10, 2013
0 Communities
3 Members
0 Resources
12 MeSH Terms